Galectin Therapeutics GAAP EPS of -$0.48 beats by $0.01
Source: SeekingAlpha
2026-03-31 08:05:25 ET
More on Galectin Therapeutics
- Galectin Therapeutics Inc. (GALT) Discusses Updated Results for Belapectin in Treatment of MASH Cirrhosis and Portal Hypertension Transcript
- Seeking Alpha’s Quant Rating on Galectin Therapeutics
- Historical earnings data for Galectin Therapeutics
- Financial information for Galectin Therapeutics
Read the full article on Seeking Alpha
For further details see:
Galectin Therapeutics GAAP EPS of -$0.48 beats by $0.01
Galectin Therapeutics Inc.
NASDAQ: GALT
GALT Trading
-2.52% G/L:
$2.325 Last:
109,380 Volume:
$2.35 Open:
GALT Latest News
May 27, 2026 08:00:00 am
Galectin Therapeutics Presents New EASL 2026 Oral and Poster Analyses Demonstrating Belapectin's Potential to Modify Disease Progression in Advanced MASH Cirrhosis
May 15, 2026 08:00:00 am
Galectin Therapeutics Reports March 31, 2026 Financial Results and Provides Business Update
May 11, 2026 08:00:00 am
Galectin Therapeutics Announces Publication of NAVIGATE Phase 2b Trial Results for Belapectin in the Journal of Hepatology
March 31, 2026 08:00:00 am
Galectin Therapeutics Reports 2025 Financial Results and Provides Business Update
GALT Stock Data
$183,102,729
30,560,103
0.23%
38
N/A
Biotechnology & Life Sciences
Healthcare
US
NORCROSS
